Array Biopharma Inc.

Genentech, Inc.

Pfizer Corporation

Enliven, Inc.

Eli Lilly and Company

Enliven Therapeutics, Inc.

Li Ren

David A Moreno

James F Blake

Andrew T Metcalf

Gabrielle R Kolakowski

Adam Wade Cook

Yutong Jiang

Julia Haas

Tony P Tang

Steven Wade Andrews

Elizabeth A McFaddin

Megan L McKenney

Barbara J Brandhuber

Oren T McNulty

Sean Douglas Aronow

Shane M Walls

Huifen Chen

Jacob Bradley Schwarz

Peter J Mohr

Ginelle A Ramann

John Joseph Gaudino

Jonas Grina

Mark Joseph Chicarelli

Ellen Ruth Laird

Kevin W Hunt

Brad Newhouse

Indrani W Gunawardana

Rustam Ferdinand Garrey

Brett Joseph Prigaro

James Collier

Joseph P Lyssikatos

Kirk D Robarge

Aihe Zhou

Donghua Dai

Dean Russell Kahn

Samuel Kintz

Lewis J Gazzard

Erik James Hicken

Michael Lyon

Allen A Thomas

Steven Mark Wenglowsky

Jane Schmidt

Patrick Michael Doerner Barbour

Alex Andrew Kellum

Alexandre Joseph Buckmelter

Shelley Allen

Bainian Feng

Wendy B Young

Mark Laurence Boys

Simon Mathieu

Janet Gunzner

Bradley Jon Newhouse

Joachim Rudolph

Zhaoyang Wen

Spencer Phillip Pajk

Joshua Ryan Dahlke

Patrick Michael Barbour

Jacob Matthew O'Leary

Eugene Tarlton

Kateri Ahrendt

Katie Keaton Brown

Kim Malesky

Joshua D Hansen

Eli M Wallace

Steven Armen Boyd

Jeongbeob Seo

Allison L Marlow

Hongqi Tian

Robert J Kaus

Christopher Stephen Siedem

Kateri A Ahrendt

Elizabeth A Mcfaddin

Jason De Meese

Oren Teague Mcnulty

Jason Demeese

Sydney Taylor Blanche

Hailong Zhang

Megan L Mckenney

Steve Do

Tanna Marie Bettendorf

Paul Lunghofer

Qiang Su

Faith Elizabeth Witkos

Jennifer Lynn Fulton

Connor James Cowdrey

Ellen Margaret Knapp

Wesley Dewitt Clark

Christopher S Siedem

Andrew Terrance Metcalf

Brett Prigaro

Dean Kahn

Oren T Mcknulty

Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I; and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Xis N and Ring A, Ring B, Ring C, X, X, R, L, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, such as e.g. cancer, e g. bladder cancer, brain cancer, breast cancer, cholangiocarcinoma, head and neck cancer, lung cancer, multiple myeloma, rhabdomyosarcoma, urethral cancer and uterine cancer. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 276 to 308; examples 1 to 30; examples A to E; tables CA to EE). An exemplary compound is e.g. 1-(3-(4-(4-(7-((3,5-dimethoxy phenyl) amino)quinoxalin-2-yl)-1H-pyrazol-1-yl)piperidine-1-carbonyl) azetidin-1-yl)prop-2-en-1-one (e.g. example 1).

Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases

Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Rand L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R, R, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R, R, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Fused heterocyclic compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X, X, Xand Xhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

Growing community of inventors

Boulder, CO, United States of America

Li Ren